Alnylam Pharmaceuticals logo

Alnylam PharmaceuticalsNASDAQ: ALNY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 June 2004

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$30.42 B
-21%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector
940.35
-21%vs. 3y high
100%vs. sector
-54%vs. 3y high
82%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:59:53 GMT
$235.88-$19.14(-7.51%)

Dividend

No data over the past 3 years
$500.92 M$578.18 M
$500.92 M-$111.57 M

Analysts recommendations

Institutional Ownership

ALNY Latest News

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
businesswire.com17 November 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These new results demonstrated that a single dose o.

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: NEUTRAL

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
seekingalpha.com27 October 2024 Sentiment: POSITIVE

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market.

Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?
zacks.com23 October 2024 Sentiment: POSITIVE

Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
zacks.com17 October 2024 Sentiment: NEUTRAL

Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
zacks.com02 October 2024 Sentiment: POSITIVE

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
businesswire.com29 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An o.

Alnylam Stock Soars 65%: Find Out What's Behind the Gains
marketbeat.com12 September 2024 Sentiment: POSITIVE

Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again.

ALNY Down Despite Positive Data From Heart Disease Drug Study
zacks.com02 September 2024 Sentiment: POSITIVE

Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership
businesswire.com30 August 2024 Sentiment: POSITIVE

DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle with its landlord, Medical Properties Trust, Inc. (“MPT”), supported by the “FILO” secured lenders under its funded debt and the official committee of unsecured creditors. Following Bankruptcy Court approval, the agreement allows for the transfer of hospitals that are governed by MPT's master lease.

What type of business is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) methods for treating genetically inherited diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company's lineup of RNAi therapeutic research focuses on four strategic therapeutic areas: genetic medicines, cardiovascular and metabolic diseases, infectious liver diseases, and CNS and eye diseases. The company has developed a unique gene deactivation-based treatment complex for inherited diseases that were previously incurable. Another 10 gene therapy products are in development.

What sector is Alnylam Pharmaceuticals in?

Alnylam Pharmaceuticals is in the Healthcare sector

What industry is Alnylam Pharmaceuticals in?

Alnylam Pharmaceuticals is in the Biotechnology industry

What country is Alnylam Pharmaceuticals from?

Alnylam Pharmaceuticals is headquartered in United States

When did Alnylam Pharmaceuticals go public?

Alnylam Pharmaceuticals initial public offering (IPO) was on 01 June 2004

What is Alnylam Pharmaceuticals website?

https://www.alnylam.com

Is Alnylam Pharmaceuticals in the S&P 500?

No, Alnylam Pharmaceuticals is not included in the S&P 500 index

Is Alnylam Pharmaceuticals in the NASDAQ 100?

No, Alnylam Pharmaceuticals is not included in the NASDAQ 100 index

Is Alnylam Pharmaceuticals in the Dow Jones?

No, Alnylam Pharmaceuticals is not included in the Dow Jones index

When was Alnylam Pharmaceuticals the previous earnings report?

No data

When does Alnylam Pharmaceuticals earnings report?

The next expected earnings date for Alnylam Pharmaceuticals is 14 February 2025